At Clayton plant, Grifols begins phase 3 testing for COVID-19 treatment | WRAL TechWire

Grifols employs more than 1,500 workers at its Clayton manufacturing facility. The 77-year-old company based in Barcelona, Spain, works in the fields of transfusion, blood banking, protein therapeutics and laboratory analysis. (This work is licensed under a Creative Commons International License.)

At Clayton plant, Grifols begins phase 3 testing for COVID-19 treatment

Since April, Grifols has been collecting blood plasma donated by healthy people who have recovered from COVID-19. The therapy contains a high and consistent concentration of purified neutralizing antibodies.